Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
Shane J. Schaffer, Chairman and CEO of Cingulate (NASDAQ: CING), appeared on the nationally syndicated Big Biz Show to discuss Cingulate's lead Phase 3 asset, CTx-1301, for the treatment of ADHD. Schaffer highlighted the company's Precision Timed Release™ (PTR™) drug delivery platform, which aims to advance next-generation pharmaceutical products. The discussion included plans for the commercialization of CTx-1301 and potential applications of PTR™ technology in other therapeutic areas. The Big Biz Show, hosted by Bob “Sully” Sullivan, is broadcast globally through partners like iHeart Radio and the American Forces Network.
Shane J. Schaffer, Presidente e CEO di Cingulate (NASDAQ: CING), è apparso nel programma Big Biz Show, syndacato a livello nazionale, per discutere l'asset principale in fase 3 di Cingulate, CTx-1301, per il trattamento dell'ADHD. Schaffer ha messo in evidenza la piattaforma di somministrazione farmaceutica Precision Timed Release™ (PTR™) dell'azienda, che mira a sviluppare prodotti farmaceutici di nuova generazione. La discussione ha incluso i piani per la commercializzazione di CTx-1301 e le potenziali applicazioni della tecnologia PTR™ in altre aree terapeutiche. Il Big Biz Show, condotto da Bob “Sully” Sullivan, è trasmesso a livello globale attraverso partner come iHeart Radio e l'American Forces Network.
Shane J. Schaffer, Presidente y CEO de Cingulate (NASDAQ: CING), apareció en el programa Big Biz Show, sindicado a nivel nacional, para discutir el activo principal en fase 3 de Cingulate, CTx-1301, para el tratamiento del TDAH. Schaffer destacó la plataforma de entrega de medicamentos Precision Timed Release™ (PTR™) de la compañía, que tiene como objetivo avanzar en los productos farmacéuticos de próxima generación. La discusión incluyó los planes para la comercialización de CTx-1301 y las posibles aplicaciones de la tecnología PTR™ en otras áreas terapéuticas. El Big Biz Show, presentado por Bob “Sully” Sullivan, se transmite a nivel global a través de socios como iHeart Radio y la American Forces Network.
세인 J. 샤퍼(Shane J. Schaffer) Cingulate(NASDAQ: CING)의 회장이자 CEO가 ADHD 치료를 위한 Cingulate의 주요 3상 자산인 CTx-1301에 대해 논의하기 위해 전국적으로 방송되는 Big Biz Show에 출연했습니다. 샤퍼는 차세대 제약 제품을 발전시키기 위한 회사의 정밀 타임 릴리스™(PTR™) 약물 전달 플랫폼을 강조했습니다. 이 논의에는 CTx-1301 상용화 계획과 다른 치료 분야에서의 PTR™ 기술 가능성에 대한 내용이 포함되었습니다. Bob “Sully” Sullivan이 진행하는 Big Biz Show는 iHeart Radio 및 American Forces Network와 같은 파트너를 통해 전 세계적으로 방송됩니다.
Shane J. Schaffer, Président et PDG de Cingulate (NASDAQ: CING), est apparu sur le Big Biz Show, syndiqué au niveau national, pour discuter de l'élément phare de Cingulate en phase 3, CTx-1301, pour le traitement du TDAH. Schaffer a mis en avant la plateforme de délivrance médicamenteuse Precision Timed Release™ (PTR™) de l'entreprise, qui vise à faire progresser les produits pharmaceutiques de nouvelle génération. La discussion a inclus des plans pour la commercialisation de CTx-1301 et des applications potentielles de la technologie PTR™ dans d'autres domaines thérapeutiques. Le Big Biz Show, animé par Bob “Sully” Sullivan, est diffusé à l'échelle mondiale via des partenaires tels qu'iHeart Radio et le American Forces Network.
Shane J. Schaffer, Vorsitzender und CEO von Cingulate (NASDAQ: CING), trat in der landesweit syndizierten Big Biz Show auf, um über Cingulates führendes Phase-3-Asset, CTx-1301, zur Behandlung von ADHS zu diskutieren. Schaffer hob die Precision Timed Release™ (PTR™) Arzneimittelabgabeplattform des Unternehmens hervor, die darauf abzielt, Arzneimittelprodukte der nächsten Generation voranzubringen. Die Diskussion beinhaltete Pläne zur Kommerzialisierung von CTx-1301 und mögliche Anwendungen der PTR™-Technologie in anderen therapeutischen Bereichen. Die Big Biz Show, moderiert von Bob “Sully” Sullivan, wird weltweit über Partner wie iHeart Radio und das American Forces Network ausgestrahlt.
- Shane J. Schaffer discussed Cingulate's lead Phase 3 asset, CTx-1301, highlighting its potential for ADHD treatment.
- Plans for the commercialization of CTx-1301 were outlined, indicating progress in bringing the product to market.
- Cingulate's proprietary PTR™ technology was showcased, potentially attracting investor interest.
- None.
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, recently joined the cast of the Big Biz Show, a business and finance broadcast, to discuss Cingulate’s lead Phase 3 asset CTx-1301 for the treatment of ADHD, its plans for commercialization, and other therapeutic areas where the company’s PTR™ technology may be applied.
The Big Biz Show is nationally syndicated and can be seen and heard around the globe across a multitude of broadcast partners including iHeart Radio and the American Forces Network. Dr. Schaffer’s interview with Big Biz host Bob “Sully” Sullivan and his cast may be viewed here.
For more information about the Big Biz Show visit bigbizshow.com.
About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information
visit cingulate.com.
Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
TDalton@cingulate.com
913-942-2301
Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200
FAQ
What did Shane Schaffer discuss on the Big Biz Show?
What is Cingulate's lead Phase 3 asset?
What technology platform does Cingulate use?
Where can the Big Biz Show be accessed?
